The changing landscape of hepatitis infection

Slides:



Advertisements
Similar presentations
Recent HCV treatment developments: In pursuit of perfectovir Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent’s Hospital, Sydney.
Advertisements

Advances in the Treatment of Chronic Hepatitis C Gregory T Everson, MD Professor of Medicine Director of Hepatology University of Colorado Denver.
Wisconsin D.O.C. Approach to Hepatitis C Treatment Edward Wall Secretary Jim Greer Bureau Director Health Services Wisconsin Department of Corrections.
Hcv infection and management in advanced liver disease
The effect of improved HCV diagnosis and treatment on public health The effect of improved HCV diagnosis and treatment on public health P Mathurin Hôpital.
Hepatitis C and You  2014 Greenview Hepatitis C Fund All Rights Reserved.
The new Treatments Dr John F Dillon. Curing one person Curing a population one person at a time.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
Senate Health Care Committee Briefing: Hepatitis C Treatment Dan Lessler, MD Chief Medical Officer November 20, 2014.
Hepatitis web study Hepatitis web study Simeprevir in HIV Coinfection, GT-1 C212 Trial Phase 3 Treatment Naïve and Treatment Experienced Dieterich D, et.
Hepatitis C What’s New Alan Kilby, M.D. Portland Gastroenterology Center Maine Medical Center VTC Sept 27, 2013.
Cost-Effectiveness of a One-Time National Hepatitis C Screening Program: Impact of a Selective Drug Reimbursement Policy CADTH Symposium April 14, 2015.
Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.
HEPATITIS 2014 BC. CHRONIC HEPATITIS B THE PROBLEM 350,000,000 PEOPLE HAVE IT IT IS TRANSMITTED MOTHER TO CHILD WHERE IT IS ENDEMIC IT CAN BE TRANSMITTED.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Prabhdeep Sidhu Candidate PharmD 2015 Western University of Health Sciences Mar 28, 2014.
Treatment of Chronic HCV Genotype 4
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 5 or 6 Robert G. Gish MD Staff Physician, Stanford University.
How to avoid a resistance issue with the first generation protease inhibitors ? O. Lada PHD Service d’Hépatologie et INSERM CRB3, AP-HP Hopital Beaujon,
Hepatitis C When, how and which patients should be treated Graham R Foster Professor of Hepatology Queen Marys School of Medicine Barts and The London.
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
Hepatitis C Nonresponders
HEPATITIS C Kimberly Klatt. CHARACTERISTICS  Virus  Enveloped  Single-stranded RNA virus  High mutation rate  6 different genotypes  Most cases.
Hepatitis web study Hepatitis web study Simeprevir versus Telaprevir with PR in GT1 ATTAIN Trial Phase 3 Treatment Experienced Reddy KR, et al. Lancet.
Antiviral HCV-Therapy - A Revolution - Dr. Jurriën G.P. Reijnders, MDL arts Afdeling Maag-, Darm-, en Leverziekten, HagaZiekenhuis,
ELPA Symposium Compassionate Use in Hepatitis C Saving lives of patients who cannot wait Thomas Berg Section of Hepatology Clinic for Gastroenterology.
Updates in the Treatment of Hepatitis C Kelsey Palmer, PharmD PGY2 Ambulatory Care Pharmacy Resident Kaiser Permanente Colorado June 4, 2016.
Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4):
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
Template ID: junglegreens Size: 36x48 Impact of Hepatitis C Screening in Outpatient Population Madhuri Chandnani MD, Pallavi Pothuri MD, Michael Stevens.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
Effectiveness of Sofosbuvir in terms of sustained virological response at 12 weeks after treatment (SVR12) BETWEEN treatment naïve AND treatment.
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 3b Treatment-Naive
Phase 3 Treatment-Naïve and Treatment-Experienced
Sofosbuvir and Ledipasvir Combination with and without Ribavirin in Patients with Hepatitis C Virus Infection; Preliminary Report of an Experience from.
Diagnosis and Point of Care Testing of Hepatitis C
Guangdi Li, Erik De Clercq
Department of Veterans Affairs
The ABCDE of Viral Hepatitis Phase 2a Liver Symposium
Update on Hepatitis C and New Treatment Options
Talking to Patients About HCV Treatment
Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.
Case 53-year-old Black Man
HCV Care in Unique Patient Populations
Boceprevir in Treatment Naive SPRINT-2
Therapeutic Background & Study Rationale
Simeprevir in HIV Coinfection, GT-1 C212 Trial
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
HCV Protease Inhibitors in Clinical Practice
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Volume 59, Issue 4, Pages (October 2013)
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
PI-Based HCV-1 Therapy: Reasons to Hold Off
Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3
From non-A, non-B hepatitis to hepatitis C virus cure
HCV Protease Inhibitors in Clinical Practice
New HCV therapies on the horizon
Martina Gambato, Sabela Lens, Miquel Navasa, Xavier Forns 
What Does the Future Hold and What Will It Mean for Patients?
Managing Hepatitis C in Vermont
Managing Hepatitis C in Vermont
Managing Hepatitis C in Vermont
Reversion of disease manifestations after HCV eradication
Presentation transcript:

The changing landscape of hepatitis infection Michael E. Herman D.O.

What’s New? For Primary Care Providers For HCV Treaters For everyone Importance of diagnosing HCV For HCV Treaters How can we improve current therapies? For everyone What’s in the horizon

Hepatitis C Infection is CURABLE! We can cure the majority of treated patients 75% of infected individuals have not been diagnosed Largely asymptomatic in first 2-4 decades Most diagnosed patients have not been treated (~75% - 80%) Toxicity of current medications

Who is Infected? Moorman AC, et al. JCI 2013;56:40-50 Pyenson B, et al. Milliman Inc, 2009

Who Cares? Most common indication for liver transplantation 33% undiagnosed baby-boomers have advanced fibrosis/cirrhosis Most common indication for liver transplantation Accounts for ½ of the 3-fold increase in hepatocellular carcinoma McGarry LJ, et al. Hepatology 2012;55:1344-1355 Davis G, et al. Gastroenterology. 2010;138(2):513-521.

USPSTF* Birth Cohort Screening Recommendations One-time screening of ALL adults born between 1945-1965 Screening of people at high risk including: Intranasal drug use Current or past IVDU Born to a mother with HCV Incarceration Getting an unregulated tattoo *US Preventive Services Task Force Moyer VA and USPSTF. Ann Intern Med 2013

Public Awareness Campaign

Benefits of Diagnosis Risk for progression, need for monitoring Lifestyle modifications Alcohol abstinence Risk to others Opportunity for treatment Possible cure Modification of natural history of the disease

HCV Cure Improves Prognosis International study, n=530, median age 48, HCV with advanced fibrosis SVR = cure Van der Meer AJ, et al. JAMA 2012;308:2584-2593

HCV Therapy Saves Lives VA Study, n=16,864, all genotypes, all stages. Backus LI et al. Clin Gastroenterolo Hepatol 2011;9:509-516

You Can Make a Difference! Screen and diagnose HCV infection

What can we offer today? “Triple Therapy” Telaprevir or Boceprevir Pegylated interferon Ribavirin 1st Generation protease inhibitor Telaprevir or Boceprevir

What can we offer today? PEG + ribavirin + sofosbuvir Genotypes 1, 4, 5 & 6, naïve Non responders ??? 12 weeks, 16-24 weeks?? Interferon free sofosbuvir + ribavirin Genotypes 2 & 3 PEG + ribavirin + simeprevir Genotype 1, naïve and non-responders 24/48 weeks response guided therapy

Interferon-free Regimens 96-97% SVR Harvoni (ledipasvir (NS5A inhibitor) / sofosbuvir (nucleotide analog NS5B polymerase inhibitor) or Viekira Pak (protease inhibitor ABT-450, a 100 mg boosting dose of ritonavir, and the NS5A inhibitor ombitasvir) for treatment.

Predicting the Future

Many Unknowns Remain….. Cost? Regimen approved? Payor “interference” 4, 6, 8, 12, 16, 24 weeks? Payor “interference” Step up therapy? Restricted access? Excessive copays? Ability to mix and match?

How Long Are You Going to Wait? There will always be something better coming down the pipeline….

Take Home Points HCV Therapy has “taken off” We can cure most patients if They are diagnosed They can afford and tolerate the drugs Research is advancing rapidly